A novel approach for liver steatosis assessment in ultrasound images using an adapted Vision-Language Foundation Model

Le résumé fourni par la source

Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent chronic liver diseases worldwide. B-mode ultrasound remains the first-line screening modality, yet its qualitative nature and inter-observer variability limit diagnostic consistency. Existing AI approaches largely rely on single-image classification with opaque outputs that do not reflect exam-level clinical reasoning. In this study, we aimed to develop a vision-language model (VLM) framework for automated, exam-level hepatic steatosis assessment from multi-image ultrasound, producing outputs aligned with the Hamaguchi scoring system. We developed a two-stage framework. First, a compact VLM (Qwen3-VL-8B-Instruct) was adapted to abdominal ultrasound using clinically grounded visual question answering on 16,232 images from 1925 patients. Second, the adapted model performed exam-level Hamaguchi scoring by jointly analyzing all ultrasound images from a given examination using a structured clinical prompt, without any additional task-specific training. Performance was evaluated on an independent cohort with liver histology specimen (179 patients, 383 images) and compared with majority-vote scoring by five expert clinicians. At the feature level, the VLM achieved 95.1% accuracy (κ=0.90-0.96), outperforming image-only baselines on clinically relevant tasks. At the exam level, AI-derived Hamaguchi scores showed strong correlation with histological steatosis (ρ=0.94), exceeding clinician performance (ρ=0.83,p<0.001). Discrimination was high across clinical steatosis severity thresholds (AUC=0.92-0.99), with significant improvements over clinicians at lower severity levels. The proposed compact vision-language framework demonstrated the ability to generate exam-level ultrasound assessments of hepatic steatosis that closely align with biopsy-derived histological severity. It supports scalable, auditable assessment for clinical screening and longitudinal monitoring.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.